Teknova Q3 revenue up 17% to $9.6M; net loss $7.6M; guidance reiterates $35-38M

Alpha Teknova, Inc.

2024-Q3 EPS reported -$0.47 revenue$28,480,000

Total revenue $9.6M (+17% YoY); Clinical Solutions up 229% to $2.0M; Lab Essentials flat at $7.2M.
GAAP net loss $7.6M ($0.15 EPS); adjusted EBITDA negative $5.0M; excludes $2.8M non-cash inventory charge.
Gross margin 0.9% (29.8% excluding $2.8M charge) vs 18.0% in Q3 2023.
Operating expenses down to $7.5M from $10.2M YoY, driven by reduced headcount and professional fees.
2024 free cash outflow outlook lowered to <$16M from <$18M; revenue guidance reaffirmed at $35-38M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.